EUCTR2013-001484-23-NL进行中（未招募）1 期
Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumaB as first-line treatment in advanced triple negative Breast cancer - Triple-B study
BOOG Study Center0 个研究点目标入组 304 人开始时间: 2013年4月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 304
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Metastasized or locally advanced incurable triple negative breast cancer; patients with stage IV at diagnosis are eligible as well. If the primary lesion is the only measurable lesion according to RECIST criteria, every locoregional treatment must be mentioned to the investigators.
- •-Histologically confirmed triple negative breast cancer (ER: < 10% nuclear staining of tumor cells on IHC; HER2: either score 0 or 1 at immunohistochemistry or negative at in situ hybridization [CISH or FISH] in case of score 2 or 3 on IHC) 47
- •-Histological confirmation of triple negative breast cancer of a metastatic lesion is
- •recommended
- •-Histological or cytological confirmation of metastatic breast cancer is required in case of
- •normal CA 15.3 levels, unless according to the principal investigators there is no doubt that the metastatic disease concerns triple negative breast cancer origin based on the course of the disease. In case patient has bone-only disease, a bone-biopsy of a metastatic lesion should be taken. A patient is only eligible if there is measurable or evaluable disease according to RECIST v1.1 (bone metastases with soft tissue masses measuring = 10mm).
- •-Primary tumor or metastasis tissue (tumor blocks, or 10 x10 µm blank slides FFPE tumor material) sent to NKI-AVL for BRCA-like testing
- •-Pretreatment histological biopsy of a metastatic lesion for the translational research questions (tumor tissue from bone metastases cannot be used). In case patient has metastatic lesions that are too risky to take a biopsy from according to the principal investigators or radiologist (including but not limited to mediastinal lymph nodus with EBUS) or the biopsy failed, patient could be included without a pretreatment biopsy of a metastatic lesion.
- •-No previous cytotoxic therapy for metastatic disease
- •-Disease-free interval of at least 12 months after completion of (neo)adjuvant paclitaxel or (neo)adjuvant platinum compound
- •-Disease-free interval of at least 6 months after completion of (neo) adjuvant docetaxel
- •-Measurable or evaluable disease according to RECIST v1.1
- •-WHO performance status of 0 or 1
- •-For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of ? 1% per year, during the treatment period and for at least 5 months after the last dose of atezolizumab/ or 5 months after the last dose of chemotherapy, whichever is later.
- •A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (? 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).
- •Examples of contraceptive methods with a failure rate of ? 1% per year include bilateral tubal ligation, male sterilization, established, proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices (IUDs), and copper IUDs.
- •-Women who are not postmenopausal (? 12 months of non?therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to initiation of study drug
- •-Adequate bone marrow function*: neutrophils = 1.5 x 10E9 cells/l, platelets =100 x 10E9
- •cells/l, Hb = 6.2 mmol/l.
- •-Normal liver function: bilirubin < 1.5 x upper limit of the normal range (ULN) (except elevated bilirubin due to Gilbert’s disease or a sim
排除标准
- •-Receptor conversion to hormone receptor positive(= 10% ER positive tumor cells 44 or HER2 positive
- •-Diagnosis of any other active malignancy prior to randomization, except those that are not believed to influence the patient’s prognosis and do not require further treatment. This includes, but is not limited to adequately treated basal cell or squamous cell skin cancer and carcinoma in situ of the cervix
- •-Other antitumor therapy within the previous 21 days,with the exception of recently started(within 21 days of randomization)endocrine therapy
- •-Radiotherapy with palliative intent within the previous 7 days before start of study treatment. After 7 days patients may be included under the condition that at least one measurable/evaluable lesion was not irradiated.If radiation is needed on bone with an extensive amount of bone marrow, the interval between treatment and randomization might be longer(at the physician’s discretion)
- •-Known CNS disease except for treated brain metastases.Treated brain metastases are defined as having no evidence of progression or hemorrhage after treatment, as ascertained by clinical examination and brain imaging during the screening period and no ongoing requirement for systemic corticosteroids.Anticonvulsants(stable dose)are allowed.Treatment for brain metastases may include whole brain radiotherapy, radiosurgery(gamma knife, LINAC or equivalent)or a combination as deemed appropriate by the treating physician. Patients with CNS metastases treated by neurosurgical resection or brain biopsy performed within 2 weeks prior to randomization will be excluded
- •-Use of denosumab;Patients who are receiving denosumab must discontinue denosumab use and replace it with a bisphosphonate instead while on study.There is no required minimum washout period for denosumab
- •-Uncontrolled serious medical or psychiatric illness
- •-Pre-existing peripheral neuropathy>grade 1(NCI-CTC AE(version 4.03))at inclusion
- •-Severe infection within 4 weeks prior to randomization
- •-Received antibiotics within 2 weeks prior to cycle 1,day 1,for a severe infection(in need of hospitalization or in need of i.v. antibiotics)
- •A non-severe infection includes,but is not limited to,an uncomplicated urinary tract infection
- •-Major surgical procedure,open biopsy,or significant traumatic injury within 28 days prior to randomization or anticipation of need for major surgical procedure during the course of the study
- •-New York Heart Association Class II or greater congestive heart failure.LVEF by MUGA or ultrasound or MRI must be=50% and should be performed within 4 weeks prior to randomization if cardiac failure is suspected.
- •-History of myocardial infarction or unstable angina or unstable arrhythmias within 3 months prior to randomization
- •-History of autoimmune disease,including but not limited to myasthenia gravis,myositis,autoimmune hepatitis,systemic lupus erythematosus,rheumatoid arthritis,inflammatory bowel disease,vascular thrombosis associated with antiphospholipid syndrome,Wegener’s granulomatosis,Sjögren’s syndrome,Guillain-Barré syndrome,multiple sclerosis,vasculitis,or glomerulonephritis
- •Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study
- •-Prior allogeneic stem cell or solid organ transplantation
- •-History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest CT scan
- •-Positive HIV test
研究者
相似试验
招募中
2 期
Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without Bevacizumab as first-line treatment in advanced triple negative Breast cancer (TRIPLE-B study);Title after protocol amendment August 12, 2017: Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumaB as first-line treatment in advanced triple negative Breast cancer (TRIPLE-B study)triple negative breast cancer10006291breast cancerNL-OMON52986BOOG Study Center304
进行中（未招募）
1 期
A phase II study assessing whether biological markers can be used to determine response to treatment with radium-223 in patients with metastatic castration resistant prostate cancer (CRPC).Castrate resistant prostate cancer with bone metastases.MedDRA version: 21.1Level: PTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10005993Term: Bone metastasesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004055-20-GBThe Royal Marsden NHS Foundation Trust38
招募中
不适用
A biomarker research of "A phase II study of second-line combination therapy with FOLFIRI plus ramucirumab in patients with RAS wild-type unresectable advanced/recurrent colorectal cancer "Colorectal cancerJPRN-UMIN000034885Japan Clinical Cancer Research Organization (JACCRO)80
进行中（未招募）
1 期
Phase II, Open Label, Randomized, Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Subcutaneous (SC) Trastuzumab in Patients with Operable or Locally Advanced/Inflammatory HER2-positive Breast CancerEUCTR2016-000435-41-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)60
进行中（未招募）
1 期
A Phase 2 Clinical Trial in Patients with Acute Myeloid Leukemia (AML).Relapsed/Refractory Acute Myeloid Leukemia (AML) with MCL-1 dependence of =40% demonstrated by mitochondrial profiling. Newly diagnosed high-risk (NDHR) AML with MCL-1 dependence of = 40% demonstrated by mitochondrial profiling.Relapsed or primary refractory AML with varying levels of MCL 1 dependence demonstrated by mitochondrial profiling.MedDRA version: 20.0Level: LLTClassification code 10060558Term: Acute myeloid leukemia recurrentSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10000887Term: Acute myeloid leukemia in remissionSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10054294Term: Acute myeloid leukemia (in remission)System Organ Class: 100000004864EUCTR2017-001178-41-GBTolero Pharmaceuticals, Inc.104